Keegan Atchison Portfolio

Microneedle Immunoglobulin Therapy, NYU Global Innovation Initiative

Immunoglobulins (Ig) are essential antibodies in the human immune system and are widely used to treat immunodeficiencies, autoimmune disorders, and acute allergic reactions. The global immunoglobulin market size is $16.24 billion, with the US responsible for $9.73 billion of that total (2023 Fortune). Currently, Ig therapy is administered either intravenously (IVIG) on a monthly basis or subcutaneously (SCIG) weekly. IVIG administration takes between 2 and 5 hours, while SCIG takes 30 to 90 minutes per session (ASCIA and Grifols). Additionally, IVIG and SCIG treatments require strict cold-chain storage (2–8°C), which limits accessibility, increases costs, and complicates rapid administration in emergency or low-resource settings.

To address these challenges, bIg G proposes a solid, microneedle patch Ig product that improves the patient experience and enables long-term storage, reduced transportation costs, and stable global supply chains. By converting immunoglobulins into a stable powdered form, patients no longer have to undergo long injection sessions. Drying methods such as lyophilization and spray drying are evaluated to minimize denaturation while producing a uniform, easily rehydratable powder. The final formulation focuses on optimizing particle size, solubility, and stability to enable rapid administration and consistent dosing.

A microneedle product has the potential to reduce reliance on cold-chain logistics, improve global accessibility to immunoglobulin therapies, and enable faster, more versatile administration in both clinical and emergency contexts. The cost of shipping can be reduced from 8% to 43% and reduce drug weight by 40x for domestic and 80x for international transport (Argonaut Manufacturing Services). By re-engineering how immunoglobulins are stored and delivered, this project aims to make antibody-based therapies more scalable, cost-effective, and adaptable to real-world healthcare needs.

PROCESS

My role is the design + research of the microneedle patch, supply chain analysis, and raw material cost estimates. I have conducted literature reviews of current Ig therapy treatments, microneedle patch applications, and existing microneedle patch patents. The product is currently under development and in talks with manufacturers. bIg G was selected by NYU’s Global Innovation Initiative, where I work alongside three other founders to improve patient experience and health.